The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease
Enabling Integration of Alzheimer Disease (AD) Prevention Study Data by Application of CDISC Standards: Extension to Biometric Monitoring Device (BMD) Assessments Arnerić, S.P., et al.; “Enabling Integration of Alzheimer Disease (AD) Prevention Study Data by Application of CDISC Standards:
The Coalition Against Major Diseases: Expanding its clinical trial database to support a disease progression model for pre-dementia Romero, K., et al.; “The Coalition Against Major Diseases: Expanding its clinical trial database to support a disease progressio
April 11, 2016 Electronic Capture of Clinical Outcome Assessment Data: Why Is It Not Used More in Clinical Studies
July 14, 2016 Presentations from ADPKD Summit 2016: Addressing the need for Clinical Endpoints in ADPKD Critical Path Institute’s John-Michael Sauer presenting on fluid-based biomarkers and how they could be applied to help...
Critical Path for Parkinson’s: Regulatory Path to Enable Targeting the Right Patients in Clinical Trials of Early Stages of Parkinson’s Disease
